Skip to content

Study · Animal study (in vivo) · mouse · 2001

6 results

Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties.

Getting SJ, Allcock GH, Flower R, Perretti M

Journal of leukocyte biology1 Jan 2001Cited by 54 (Europe PMC)

PMID11200074 (opens in a new tab)DOI10.1189/jlb.69.1.98 (opens in a new tab)PepBankPUB-11200074
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with urate crystal-induced peritoneal inflammation, systemic MTII inhibited accumulation of KC.

    In plain wordsIn mice with experimental gout, MTII treatment reduced the build-up of the inflammatory signal KC.

    Peptide
    Melanotan II
    Outcome
    DecreaseKC accumulation in the peritoneal cavity
    Study

    mousen: not reported in source

    murine model of experimental gout
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Systemic treatment of mice with gamma2-melanocyte-stimulating hormone (gamma2-MSH) and the synthetic agonist MTII inhibited accumulation of KC, interleukin-1 beta (IL-1beta), and PMN elicited by urate crystals in the peritoneal cavity.
    1 context sentence
    Summary · context
    The effects of the natural and synthetic ligands for the melanocortin receptor type 3 (MC3-R) have been evaluated in a murine model of experimental gout.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with urate crystal-induced peritoneal inflammation, systemic MTII inhibited accumulation of interleukin-1 beta.

    In plain wordsIn mice with experimental gout, MTII treatment reduced the build-up of the inflammatory signal interleukin-1 beta.

    Peptide
    Melanotan II
    Outcome
    DecreaseIL-1 beta accumulation in the peritoneal cavity
    Study

    mousen: not reported in source

    murine model of experimental gout
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Systemic treatment of mice with gamma2-melanocyte-stimulating hormone (gamma2-MSH) and the synthetic agonist MTII inhibited accumulation of KC, interleukin-1 beta (IL-1beta), and PMN elicited by urate crystals in the peritoneal cavity.
    1 context sentence
    Summary · context
    The effects of the natural and synthetic ligands for the melanocortin receptor type 3 (MC3-R) have been evaluated in a murine model of experimental gout.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with urate crystal-induced peritoneal inflammation, systemic MTII inhibited accumulation of PMN (neutrophils).

    In plain wordsIn mice with experimental gout, MTII treatment reduced the build-up of white blood cells called PMN.

    Peptide
    Melanotan II
    Outcome
    DecreasePMN accumulation in the peritoneal cavity
    Study

    mousen: not reported in source

    murine model of experimental gout
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Systemic treatment of mice with gamma2-melanocyte-stimulating hormone (gamma2-MSH) and the synthetic agonist MTII inhibited accumulation of KC, interleukin-1 beta (IL-1beta), and PMN elicited by urate crystals in the peritoneal cavity.
    1 context sentence
    Summary · context
    The effects of the natural and synthetic ligands for the melanocortin receptor type 3 (MC3-R) have been evaluated in a murine model of experimental gout.
  4. 04AnimalAnimal study (in vivo)Mechanism

    The mixed MC3/4-R antagonist SHU9119 prevented the inhibitory actions of MTII in vitro and in vivo, whereas the MC4-R antagonist HS024 did not.

    In plain wordsIn mice and cells, an MC3/MC4 receptor blocker stopped the anti-inflammatory action of MTII, but an MC4-only blocker did not.

    Peptide
    Melanotan II
    Outcome
    Not applicableBlockade of MTII anti-inflammatory action by SHU9119
    Study

    mousen: not reported in source

    murine model of experimental gout
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The mixed MC3/4-R antagonist SHU9119 prevented the inhibitory actions of gamma2-MSH and MTII in vitro and in vivo, whereas the selective MC4-R antagonist HS024 was without effect.
    1 context sentence
    Summary · context
    The effects of the natural and synthetic ligands for the melanocortin receptor type 3 (MC3-R) have been evaluated in a murine model of experimental gout.
  5. 05LabIn vitro (cells)Activity measurement

    In macrophages in vitro, MTII inhibited activation, measured as release of KC.

    In plain wordsIn cells, MTII reduced the release of the inflammatory signal KC from macrophages.

    Peptide
    Melanotan II
    Outcome
    DecreaseMacrophage KC release
    Study

    mousen: not reported in source

    macrophages
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro, macrophage (Mø) activation, determined as release of KC and IL-1beta, was inhibited by gamma2-MSH and MTII.
    1 context sentence
    Summary · context
    The effects of the natural and synthetic ligands for the melanocortin receptor type 3 (MC3-R) have been evaluated in a murine model of experimental gout.
  6. 06LabIn vitro (cells)Activity measurement

    In macrophages in vitro, MTII inhibited activation, measured as release of interleukin-1 beta.

    In plain wordsIn cells, MTII reduced the release of the inflammatory signal interleukin-1 beta from macrophages.

    Peptide
    Melanotan II
    Outcome
    DecreaseMacrophage IL-1 beta release
    Study

    mousen: not reported in source

    macrophages
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro, macrophage (Mø) activation, determined as release of KC and IL-1beta, was inhibited by gamma2-MSH and MTII.
    1 context sentence
    Summary · context
    The effects of the natural and synthetic ligands for the melanocortin receptor type 3 (MC3-R) have been evaluated in a murine model of experimental gout.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.